Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

Perez Valderrama, B.Castellano Gauna, D.Pinto Marin, A.Mellado Gonzalez, B.Puente, J.Climent Duran, M. A.Domenech, M.Vazquez Mazon, F. J.Perez Gracia, J. L.Bonfill, T.Morales Barrera, R.Ballester Navarro, I.Garcia del Muro, X.Maroto, P.Juan Vidal, O. J.Rodriguez-Vida, A.Bellmunt, J.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27216enPhase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapyconference outputopen access10.1016/j.annonc.2020.08.22561569-8041http://www.annalsofoncology.org/article/S0923753420423385/pdf573469102654